AbCellera Biologics Inc. (ABCL) Current Ratio
- Current ratio · latest quarter: Value 12.77×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 12.77× | Current assets / current liabilities. $679.23M ÷ $53.19M ≈ 12.77× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 679.23M USD | Assets, Current |
| Current obligations | 53.19M USD | Liabilities, Current |
| Cash and equivalents | 120.06M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 7.58M USD | Inventory, Net |
| Payables | (m) | |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $679.23M | $53.19M | $120.06M | (m) | (m) | $7.58M | (m) | (m) | 12.77× |
| 2026-03-31 | $664.60M | $47.29M | $77.06M | (m) | (m) | $7.86M | (m) | (m) | 14.05× |
| 2025-12-31 | $728.23M | $64.31M | $128.51M | (m) | (m) | $6.34M | (m) | (m) | 11.32× |
| 2025-09-30 | $695.14M | $68.80M | $83.16M | (m) | (m) | (m) | (m) | (m) | 10.10× |
| 2025-06-30 | $742.14M | $67.02M | $92.44M | (m) | (m) | (m) | (m) | (m) | 11.07× |
| 2025-03-31 | $764.98M | $75.40M | $159.27M | (m) | (m) | (m) | (m) | (m) | 10.15× |
| 2024-12-31 | $751.37M | $76.61M | $156.32M | (m) | (m) | $0.00 | (m) | (m) | 9.81× |
| 2024-09-30 | $742.88M | $79.57M | $126.64M | (m) | (m) | (m) | (m) | (m) | 9.34× |
| 2024-06-30 | $771.55M | $70.38M | $148.31M | (m) | (m) | (m) | (m) | (m) | 10.96× |
| 2024-03-31 | $813.95M | $104.88M | $123.57M | (m) | (m) | (m) | (m) | (m) | 7.76× |
| 2023-12-31 | $871.99M | $119.01M | $133.32M | (m) | (m) | (m) | (m) | (m) | 7.33× |
| 2023-09-30 | $919.52M | $110.24M | $172.42M | (m) | (m) | (m) | (m) | (m) | 8.34× |
| 2023-06-30 | $930.74M | $118.91M | $179.75M | (m) | (m) | (m) | (m) | (m) | 7.83× |
| 2023-03-31 | $940.65M | $89.59M | $193.02M | (m) | (m) | (m) | (m) | (m) | 10.50× |
| 2022-12-31 | $1.03B | $118.32M | $386.54M | (m) | (m) | (m) | (m) | (m) | 8.67× |
| 2022-09-30 | $1.05B | $106.05M | $371.97M | (m) | (m) | (m) | (m) | (m) | 9.86× |
| 2022-06-30 | $1.14B | $221.14M | $790.62M | (m) | (m) | (m) | (m) | (m) | 5.17× |
| 2022-03-31 | $1.17B | $213.42M | $545.72M | (m) | (m) | (m) | (m) | (m) | 5.50× |
| 2021-12-31 | $929.80M | $120.68M | $476.14M | (m) | (m) | (m) | (m) | (m) | 7.70× |
| 2021-09-30 | $803.75M | $49.55M | $517.69M | (m) | (m) | (m) | (m) | (m) | 16.22× |
| 2021-06-30 | $864.00M | $69.76M | $792.57M | (m) | $2.80M | (m) | (m) | (m) | 12.39× |
| 2021-03-31 | $907.98M | $88.39M | $685.79M | (m) | $23.37M | (m) | (m) | (m) | 10.27× |
| 2020-12-31 | $813.33M | $103.49M | $594.12M | (m) | (m) | (m) | (m) | (m) | 7.86× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |